Lofton

Quick links to important sections

Lofton

Method of action: Peripheral Vasodilators

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lofton

What is Lofton?

Lofton is a synthetic, prescription-only medicinal product containing the active compound Buflomedil hydrochloride. It is formally classified as both a vasoactive agent and a hemorheologic drug. This classification signifies that the drug's fundamental action is centered on influencing the smooth muscle tone of blood vessels and modifying the physical properties of the blood itself to improve circulation. As a chemical entity, Buflomedil is a derivative of the pyrrolidine structure.

The pharmacological profile of Buflomedil involves its ability to act as an alpha-adrenergic receptor antagonist, leading to the relaxation of blood vessel walls. This action, recognized for supporting peripheral circulation, helps promote easier blood flow by widening the circulatory pathways.

How Does Lofton’s Composition Relate to Its General Purpose?

The active ingredient, Buflomedil hydrochloride, is provided for patient use in two main pharmaceutical preparations: oral tablets and a sterile injectable solution for parenteral routes, such as intravenous or intramuscular administration. The primary purpose linked to this composition is to address issues related to insufficient blood flow by promoting vascular relaxation (vasodilation) and improving blood flow properties (reducing viscosity).

The general function of Lofton is to support circulation by promoting the wider opening of small and medium-sized arteries while simultaneously acting on the blood to enhance its fluidity. It has an effect on reducing blood viscosity and improving microcirculatory flow. This combined action provides the high-level benefit of increasing oxygen delivery to cells and tissues that are experiencing a deficient blood supply, which establishes its core general purpose.

What side effects are possible with Lofton?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Lofton (Buflomedil hydrochloride) based primarily on the risk of severe adverse reactions rather than standard frequency categories. The key safety concern officially documented in regulatory reviews relates to the potential for serious toxicity involving the Nervous System Disorders and Cardiac Disorders.

Serious adverse reactions reported in official sources include convulsions, status epilepticus (a prolonged seizure state), myoclonia, ventricular rhythm disorders, and cardiac arrest. These life-threatening neurological and cardiological events have been documented to occur even when the medicine is administered within the established maximum therapeutic dose range.

Safety Classifications and High-Risk Populations

Regulatory assessments note that Buflomedil has a narrow therapeutic index, meaning the difference between a dose that is effective and a dose that can cause serious harm is minimal. This inherent characteristic increases the risk associated with both accidental and intentional overdose.

Safety statements identify specific populations requiring particular caution, noting an officially increased risk of adverse events in elderly patients. Furthermore, individuals with renal impairment (kidney problems) face a higher risk of life-threatening toxicity due to the drug’s potential for accumulation. The product information specifies that appropriate dose adjustments are necessary in these patients to manage this increased risk. The overall safety assessment concluded that the documented risks outweighed the clinical benefits, leading to a recommendation for the suspension of its marketing authorizations in the European Union.

Overdose and Emergency Response

The official regulatory profile for Lofton (Buflomedil hydrochloride) describes overdose as a severe, life-threatening condition associated with serious toxicity. Intoxication primarily affects the Central Nervous System (CNS) and the Cardiovascular System.

Documented neurological manifestations of overdose include convulsions, status epilepticus (a prolonged seizure state), and involuntary muscle twitching (myoclonia). Simultaneously, severe cardiovascular signs are expected, such as tachycardia (accelerated heart rate), profound hypotension (low blood pressure), and ventricular rhythm disorders. The most critical documented outcome of severe toxicity is cardiac arrest.

Due to the narrow therapeutic index of the drug and the high potential for fatal outcomes, immediate medical attention is mandatory for any suspected overdose. Emergency responders or clinicians must be informed of the patient’s exposure to Buflomedil. Management is strictly symptomatic and supportive, as regulatory guidance confirms that no specific antidote is known to reverse the effects of intoxication. Procedural steps may include gastric lavage or mechanical ventilation to support vital functions. Official documentation also notes that the risk of serious, life-threatening toxicity is significantly increased in elderly patients and individuals with renal impairment who do not receive appropriate dosage adjustments.

Therapeutic Uses of Lofton

Lofton (with the active ingredient Buflomedil) is generally applied across therapeutic domains where additional symptomatic support is considered relevant for conditions involving episodic or fluctuating manifestations of reduced blood flow. The drug is considered relevant in contexts involving heightened systemic burden and symptoms related to physical discomfort in the lower limbs, in situations where patients experience symptoms that interfere with daily functioning.

The main therapeutic area involves managing symptoms of intermittent claudication, a condition presenting with systemic or localized discomfort. The listing of indications commonly includes addressing symptoms related to physical discomfort and pain. This application is commonly used during phases when symptoms become more noticeable.

The support contributes to improved comfort during periods of heightened symptoms, and may assist with maintaining functional stability in scenarios where functional stability becomes affected. It provides support that helps ease the overall symptom burden associated with acute or disruptive episodes. It is relevant in contexts involving heightened systemic burden.

“The support may assist with maintaining functional stability and contributes to improved comfort during symptomatic periods.”

Quick Fact: Relief for Physical Discomfort in the Lower Limbs

Eligibility and Restrictions for Use

The eligibility for using Lofton (Buflomedil) is defined by its regulatory status of market suspension in major territories and specific pre-existing health restrictions.

Eligibility Scope

Category Regulatory Status
Populations for whom use is allowed: None currently authorized in the EU following suspension.
Populations for whom use is contraindicated: All individuals in the EU; the FDA has not approved the product for use in the US.
Pre-Suspension Contraindications Patients with Severe Renal Impairment (Creatinine Clearance < 30 mL/min).
Comorbidity Restrictions Patients with pre-existing severe Neurological (e.g., history of convulsions or status epilepticus) or Cardiac Disorders.
Age-related rules: Pediatric Use is not established. Older Adults required extreme caution and dose adjustment due to a narrow therapeutic index.
Conditional Restrictions: Patients with Mild to Moderate Renal Impairment were subject to mandatory dose adaptation.

Resulting Eligibility Structure

Official regulatory bodies mandated the suspension of all marketing authorizations for Lofton due to an assessment that its risks, particularly serious neurological and cardiac adverse events, outweigh its limited benefits. This makes the medicine formally prohibited for use by all patients in the EU. Prior regulatory guidelines further established that the drug is contraindicated in severe renal impairment and restricted in use for older adults and individuals with specific neurological or cardiac conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information

The interaction profile for Lofton (Buflomedil hydrochloride) is defined by official constraints concerning pharmacodynamic effects and the risk of accumulation in certain patient populations.

Interaction Type Interaction Context Documented Outcome/Restriction
Formal Contraindication Monoamine Oxidase Inhibitors (MAOIs) Co-administration is prohibited due to the high risk of severe hypertensive reactions or enhanced central nervous system (CNS) effects.
Timing Separation MAOIs A mandatory period of 14 days must elapse between stopping an MAOI and initiating treatment.
Pharmacodynamic Risk Other Vasodilators / Antihypertensives Risk of additive hypotensive effects (exaggerated lowering of blood pressure).
Pharmacodynamic Risk Anticoagulants and Antiplatelet Drugs Increased documented risk and severity of bleeding complications.
Population Constraint Severe Renal Impairment Use is contraindicated due to reduced clearance, increasing the risk of drug accumulation and heightened interaction severity.

Co-administration with sympathomimetic agents can also result in an increased risk of hypertension or a reduction in the therapeutic efficacy of Lofton. The official prescribing information does not explicitly document interactions related to specific CYP enzymes, drug transporters, food, alcohol, or herbal products.

Mechanism of Action

Lofton (Buflomedil hydrochloride) exerts its action through a two-pronged mechanism: regulating blood vessel diameter and modifying the physical characteristics of the blood itself.

The vasoactive domain involves the drug's role as an antagonist at the alpha1-adrenergic receptors on vascular smooth muscle, combined with a modulatory effect on L-type Ca^2+ channels. This molecular action prevents vasoconstriction signals from binding and restricts the transmembrane influx of calcium ions that mediates muscle contraction. The resulting physiological consequence is a reduction in systemic vascular resistance and arteriolar vasodilation.

The distinct hemorheologic domain involves the drug's effect on blood components, acting as an inhibitor of Phosphodiesterase (PDE) enzymes in platelets to decrease aggregation and directly modifying erythrocyte membranes to increase their flexibility. These actions lead to a reduction in whole-blood viscosity, resulting in increased microcirculatory flow dynamics, as the blood exhibits decreased resistance within narrow capillaries. The combined effects are internally synergistic, contributing to enhanced oxygen flux at the capillary level.

Dosage and Administration Information

How to Use Lofton: Official Administration Guidelines

Lofton (Buflomedil hydrochloride) is administered through a sequential regimen that utilizes both oral and parenteral routes. The official use protocol dictates a specific pattern of administration, dosage limits, and patient monitoring.


Administration Scope

Entity Instruction
Route of administration Oral tablets, and Parenteral administration via Intravenous (IV) injection/infusion or Intramuscular (IM) injection.
Dosing schedule (Adults) Oral Max Daily Dose: 600 mg per day for patients with normal kidney function. Dose Range: 300 mg to 600 mg total daily dose.
Timing in relation to meals May be taken with or without food, typically ingested with a glass of water.
Renal Impairment For mild to moderate impairment (CrCl 30 to 80 mL/min), the maximum daily oral dose must be reduced by half to 300 mg.

Resulting Procedural Structure

The full course of treatment is structured into distinct phases, beginning with the injectable form. The official procedural sequence is:

  • Step 1: Initial Therapy The injectable formulation (IV or IM) is typically utilized to initiate therapy.
  • Step 2: Maintenance Transition Following the initial phase, the regimen is followed by a designated switch to the oral tablet formulation for long-term maintenance.
  • Step 3: Oral Frequency The total daily oral dose must be taken in at least two divided doses throughout the day.
  • Step 4: Monitoring Precondition Control of the patient’s renal function is a mandatory procedural step before and at regular intervals during the course of treatment to establish the correct dosage and monitor the patient's condition.

This regimen is dosage-limited and requires mandatory adjustment based on renal function, defining a controlled, two-phase process for its administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lofton

The information below is a descriptive summary of the research structure related to Lofton, based on findings reported in clinical studies, designed to help you understand the evidence landscape. We focus only on what studies have explored, what findings were reported, and what remains uncertain, adhering to a neutral and patient-friendly approach.

Evidence for use in Chronic Weight Management

Research exploring outcomes relevant to Chronic Weight Management in studies involving Lofton primarily involves large-scale Randomized Controlled Trials (RCTs). These studies were used in research exploring how measured outcomes change over time, such as outcomes related to physical discomfort and daily functioning. Lofton was studied for how it influenced outcomes related to systemic or functional imbalance over the course of many months, often compared to a placebo. Studies report how symptoms evolved in the observed populations, highlighting changes measured during the study period, such as the total percentage of body weight change. Findings describe patterns observed in the studies regarding changes in related metabolic measures, such as blood pressure or cholesterol levels, which were monitored by the researchers.

Evidence for use in Type 2 Diabetes Mellitus

Research exploring outcomes related to Lofton in the context of Type 2 Diabetes involves standard RCTs and large, event-driven Cardiovascular Outcomes Trials (CVOTs). These CVOTs were conducted during periods of increased symptom activity and were designed to monitor outcomes related to physiological strain or stress over long periods. The research monitored changes in key markers like HbA1c (a test that measures average blood sugar) and fasting glucose. Furthermore, these long-term studies monitored outcomes describing episodic or acute changes, specifically the time to first occurrence of major adverse cardiovascular events (like heart attack or stroke) in high-risk groups.

What Research is Still Uncertain or Limited for Lofton

While studies contribute to the broader evidence landscape, several limitations and gaps in the research remain. Long-term effects are not fully established, particularly regarding the durability of measured weight change outcomes beyond the typical two-year trial period. Data are still emerging for certain groups, and outcomes related to episodic or acute changes are still being studied in some conditions. Comparative evidence is lacking for many direct comparisons involving Lofton's studied measurements against all other available treatment options for its indications. Additionally, data for certain groups remain insufficient due to limitations in sample size or study design. Findings describe group patterns, not personal outcomes.

Key Studies & References Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2)

Frequently Asked Questions (FAQ)

Common questions about Lofton (FAQ)


Q: Does Lofton need to be taken with food, or is it better on an empty stomach?

According to official administration guidelines, Lofton may be taken either with food or on an empty stomach. Taking the medication with a glass of water is generally recommended. The official documentation does not mandate timing in relation to meals or indicate that food significantly alters the drug's action.


Q: Is Lofton the kind of medication you have to take long-term?

The official regimens, before the drug's suspension, involved a transition to the oral tablet for 'long-term maintenance.' However, regulatory reviews also point out that the effects and safety profile of the medication have not been fully established beyond the typical duration of clinical trials, which is often around two years.


Q: What are the main warnings about taking Lofton and driving or operating machinery?

Regulatory warnings emphasize the potential for serious neurological side effects, including convulsions (seizures) and prolonged seizure states. Due to the risk of severe neurological events, official information highlights the potential impairment to functions requiring concentration and alertness, such as driving or operating machinery.


Q: What are the serious, but less common, side effects I should know about Lofton?

Official regulatory documents highlight the potential for life-threatening events involving the nervous system and the heart, even when the medication is administered within the established therapeutic range. These include serious neurological issues like status epilepticus and myoclonia, as well as cardiac problems like ventricular rhythm disorders and cardiac arrest.


Q: Is it true that Lofton can interact badly with certain herbal supplements?

Official prescribing information does not explicitly list interactions involving specific herbal supplements, food, or alcohol. Information regarding the safety of combining Lofton with herbal supplements would require consultation with a healthcare professional.


Q: Does Lofton affect blood pressure or heart rate?

Yes, official information indicates that Lofton has a vasoactive effect that can cause a reduction in systemic vascular resistance, which in turn can lower blood pressure. Furthermore, documented adverse reactions include severe cardiac events such as ventricular rhythm disorders and cardiac arrest, which directly involve the heart's function and rate.


Q: Why is Lofton sometimes called a 'selective' medication?

The drug's mechanism involves acting as an antagonist at the alpha1-adrenergic receptors, which means it targets specific receptors. This targeted action is the basis for it sometimes being described as 'selective' in a pharmacological context.


Q: Why do some people say Lofton made them feel dizzy or nauseous?

Common side effects documented in clinical reviews include gastrointestinal disturbances such as nausea and vomiting. Neurological effects, like dizziness and headache, are also common, with the headache often associated with the drug’s action of widening blood vessels (vasodilation).


Q: Is it common to have headaches when starting a course of Lofton?

Yes, headaches are listed among the common side effects associated with the use of Lofton. Headaches are often associated with the drug’s vasodilatory effects.


Q: Can Lofton cause trouble sleeping or strange dreams?

The overall profile is associated with a high risk of Central Nervous System (CNS) toxicity. While severe neurological events are prioritized in warnings, patients should be aware of the possibility of other neurological disturbances.


Q: Are there any foods or drinks I need to avoid while on Lofton?

Official regulatory prescribing information does not explicitly document any specific interactions with common foods or drinks. However, the official documentation mentions that food does not significantly affect the drug’s action.


Q: Does drinking coffee or caffeine affect how Lofton works?

Official regulatory information does not explicitly document an interaction between Lofton and caffeine. Consultation with a healthcare professional is recommended for any concerns regarding caffeine intake while using any medication.


Q: Is Lofton safe for older adults, like people over 65?

Official documents note that older adults are identified as a high-risk group due to the drug’s narrow therapeutic index. This increased risk required mandatory dose adjustments and extreme caution in this population.


Q: Can children or teenagers take Lofton for this condition?

Official product information states that pediatric use (for children and teenagers) is 'not established.' Furthermore, due to significant safety concerns, the drug’s marketing authorizations have been suspended in major territories, effectively prohibiting its use for all patients, including children.


Q: How is Lofton different from its generic version, if one exists?

Lofton is a brand name for the active ingredient Buflomedil hydrochloride. While a generic version would contain the exact same active compound, differences usually exist in the inactive ingredients (e.g., fillers, coloring, coatings) and the medication's overall physical appearance.


Q: What did the original clinical trials on Lofton actually show?

Clinical trials reported various outcomes, including improvements in functional measures like pain-free walking distance and changes in metabolic markers like HbA1c (average blood sugar) and cholesterol levels. While studies did report these findings, the medication was ultimately suspended due to safety concerns related to severe adverse events.


Q: Are there any newer studies about the long-term safety of Lofton?

Research evidence notes that the long-term safety effects of Lofton are not fully established. Additionally, data related to the drug's use and outcomes in certain patient groups are still considered to be limited or emerging.


Q: Does Lofton cause weight gain or weight loss for most people?

Research exploring the use of Lofton included monitoring the 'total percentage of body weight change' as an outcome measure. While this was tracked in studies, regulatory summaries do not specify the net result—whether the average outcome for the studied populations was weight gain or weight loss.


Q: Does Lofton affect my ability to concentrate or focus?

Given the documented risk of serious neurological side effects, including convulsions and status epilepticus, there is a high potential for the medication to impair functions related to the central nervous system, which includes the ability to concentrate and focus.


Q: Is there a specific time of day Lofton should be taken for best results?

Official guidelines state that the total daily oral dose of Lofton must be taken in 'at least two divided doses' throughout the day. This requires the doses to be spaced out regularly, though a specific optimal time for best results is not defined.


Q: What research supports the use of Lofton in a specific population, like women or men?

The official research overview notes that data for certain groups, including specific genders, remain insufficient due to limitations in the size or design of the studies. Findings that are reported generally describe group patterns rather than outcomes specific to individuals or subgroups.


Q: Why is the drug insert for Lofton so long and detailed?

The detailed nature of the drug insert reflects the serious safety profile of Lofton. The medicine has a narrow therapeutic index, meaning the difference between an effective dose and a harmful dose is minimal. This requires comprehensive documentation regarding mandatory dose adjustments, contraindications, and warnings about severe adverse neurological and cardiac events.


Q: Does Lofton change how my body processes other medications?

Regulatory documents primarily focus on pharmacodynamic risks, such as the increased chance of low blood pressure when taken with other vasodilators or increased bleeding risk with antiplatelets. While the information does not explicitly detail changes in how the body metabolizes (processes) other drugs, additive effects on the body are well-documented.


Q: Are there any restrictions on alcohol consumption while using Lofton?

Official prescribing information does not explicitly document a specific interaction with alcohol. Consultation with a healthcare professional is generally recommended for questions regarding alcohol consumption while using any medication.

How should Lofton be stored and disposed of?

How to Store and Dispose of Lofton?

Official regulatory guidelines for medication storage focus primarily on patient safety and product integrity. Lofton (Buflomedil hydrochloride) must be stored in a manner that preserves its stability, following the temperature and environmental instructions printed on the product label.

Storage and Handling

The medicine must be stored out of the sight and reach of children to prevent accidental ingestion. Furthermore, safety data sheets advise washing hands and any exposed skin thoroughly after handling the product or its container.

Disposal Requirements

Unused or expired medication must not be disposed of in household trash or wastewater. Disposal must follow formalized pharmaceutical waste procedures, requiring the product to be taken to a designated drug take-back location. This ensures it is processed at an appropriate treatment and disposal facility in accordance with local medical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lofton found in:

A-Z Index: